Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong Sells 14,836 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 14,836 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $48,662.08. Following the transaction, the chief financial officer now directly owns 482,572 shares of the company’s stock, valued at $1,582,836.16. This represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Neuronetics Stock Performance

Shares of STIM opened at $3.97 on Thursday. Neuronetics, Inc. has a 12 month low of $0.52 and a 12 month high of $5.07. The firm has a fifty day simple moving average of $2.09 and a 200 day simple moving average of $1.38. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16.

Institutional Investors Weigh In On Neuronetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its holdings in shares of Neuronetics by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after acquiring an additional 8,466 shares in the last quarter. Tradewinds LLC. acquired a new position in Neuronetics during the fourth quarter valued at approximately $32,000. JPMorgan Chase & Co. boosted its position in Neuronetics by 10,954.1% during the fourth quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after purchasing an additional 54,442 shares during the last quarter. David J Yvars Group grew its stake in Neuronetics by 47.1% in the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after purchasing an additional 14,825 shares in the last quarter. Finally, HighTower Advisors LLC increased its position in shares of Neuronetics by 55.5% during the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after purchasing an additional 87,816 shares during the last quarter. 53.59% of the stock is owned by institutional investors.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.